Company profilePharmaceutical#134 of 1,318 in Pakistan✓ No DRAP alerts

Fedro Pharmaceutical Labs Pvt Ltd

Pharmaceutical company · 126 brands · 133 molecules

Ranked #13 of 16 companies in Antimycobacterials (Antituberculosis)

126 registered products 48 pharmaceutical brands 133 distinct molecules 0 DRAP alerts

Company overview

126
registered products
48
pharmaceutical brands
133
distinct molecules
3
therapeutic classes
0
DRAP alerts

Fedro Pharmaceutical Labs Pvt Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 126 product registrations across 133 distinct molecules. It is the 134th largest registrant in Pakistan by product count, and ranks 13th of 16 in Antimycobacterials (Antituberculosis). Its portfolio is concentrated in Antimycobacterials (Antituberculosis) and Pain Management. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Fedro

70 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Pain Management 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

68
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202568

Top molecules by brand count

Cephalexin6 brands
Cefixime5 brands
Amlodipine4 brands
Azithromycin4 brands
Ibuprofen3 brands
Levofloxacin3 brands
Artemether3 brands
Omeprazole3 brands

Therapeutic classes

Antimycobacterials (Antituberculosis) · 1Pain Management · 1Gastro · 1

Conditions treated

Pain Killers · 1Ulcer/Reflux/Flatulence/Acidity · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official126 products · Rs 38.59 – Rs 2,516.28
Servaid2 products · Rs 280 – Rs 323.12
Median across source: Rs 301.56

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SEARLE PAKISTAN (PVT.) LTD. holds 213 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline
IRZA PHARMA (PVT) LTD. holds 94 molecules not in this portfolio
AcetazolamideAcyclovirAdrenalineAlbuterolAmikacinAmoxycillin Amoxycillin
SEMOS PHARMACEUTICALS (PVT) LTD. holds 41 molecules not in this portfolio
Amodiaquine 150MgArtesunateAscorbic AcidBisacodylBuprenorphineCefotaxime

Get the full profile for Fedro

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.